DR. PAUL B CHAPMAN, MD
Osteopathic Medicine at York Ave, New York, NY
License number
New York 174210
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
1275 York Ave, New York, NY 10021
Phone
(646) 227-3813
Personal information
See more information about PAUL B CHAPMAN at radaris.comName
Address
Phone
4420 Winton Rd, Montour Falls, NY 14865
57 Bedford St, Rochester, NY 14609
3547 State Route 79, Harpursville, NY 13787
30 Alpine Dr APT G, Wappingers Fl, NY 12590
31 Robble Ave, Endicott, NY 13760
Professional information
Paul Chapman
Location:
Greater New York City Area
Industry:
Marketing and Advertising
Skills:
Return on Investment, SEM, PPC, SEO, Direct Response, Lead Generation, CPL, E-commerce, Business Performance Management, Subscriptions, Digital Strategy, Digital Media, Digital Marketing, Online Advertising, Mobile Marketing, DoubleClick, Omniture, Media Buying, Behavioral Targeting, Affiliate Marketing, Display Advertising
President At Aicships Inc
Position:
President at AICships Inc
Location:
Greater New York City Area
Industry:
Transportation/Trucking/Railroad
Work:
AICships Inc
-
President
SSI Navigation
1974 - 1975
-
Vice-President
Owner At Chapman Media Associates
Position:
Owner at Chapman media associates
Location:
Greater New York City Area
Industry:
Broadcast Media
Work:
Chapman media associates
-
Owner
Anti-Idiotypic Antibody Which Induces An Immune Response Against A Glycosphingolipid And Use Thereof
US Patent:
6432402, Aug 13, 2002
Filed:
May 23, 1995
Appl. No.:
08/447412
Inventors:
Paul B. Chapman - New York NY
Alan N. Houghton - New York NY
Alan N. Houghton - New York NY
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
A61K 39395
US Classification:
4241311, 4241301, 4241331, 4241841, 4241971, 42419711, 435325, 435326, 435327, 435346, 5303871, 5303872, 5303873, 5303875, 5303881, 53038825, 5303891, 5303893, 530810, 530808, 530806
Abstract:
The present invention provides an anti-idiotypic monoclonal antibody which specifically induces an immune response against a glycosphingolipid. Additionally, this invention provides a method of producing the anti-idiotypic monoclonal antibody. Finally, this invention provides a composition of matter comprising an effective amount of a cytokine and a melanoma ganglioside-specific antibody attached to a carrier.
Compositions And Method For Treatment Of Cancer Using Monoclonal Antibody Against G.sub.d3 Ganglioside Together With Il-2
US Patent:
5104652, Apr 14, 1992
Filed:
Jul 5, 1990
Appl. No.:
7/549238
Inventors:
Alan N. Houghton - New York NY
Karl Welte - New York NY
Glenn Miller - Port Washington NY
Paul Chapman - New York NY
Lloyd J. Old - New York NY
Karl Welte - New York NY
Glenn Miller - Port Washington NY
Paul Chapman - New York NY
Lloyd J. Old - New York NY
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
A61K 3702, A61K 3900, C12N 502
US Classification:
424 852
Abstract:
Cell surface gangliosides are presumed to play a role in cell growth and differentiation. Using monoclonal antibodies directed against G. sub. D3, a disialoganglioside expressed predominantly by cells of neuroectodermal origin, we have found that G. sub. D3 is expressed by a subpopulation of cells of the immune system including: a) fetal thymocytes in subcortical regions and near vessels, 2) lymph node lymphocytes in interfollicular areas and near vessels, and 3) a small subset of T cells in the peripheral blood. Mouse monoclonal antibodies (two IgGs, one IgM and F(ab'). sub. 2 fragments) reacting with G. sub. D3 were found to stimulate proliferation of T cells derived from peripheral blood. Proliferation induced by binding to G. sub. D3 could be augmented by exogenous IL-2, PMA, PHA or Protein A.
Anti-Idiotypic Antibody Vaccines
US Patent:
5792455, Aug 11, 1998
Filed:
Mar 21, 1996
Appl. No.:
8/619217
Inventors:
Paul B. Chapman - New York NY
Alan N. Houghton - New York NY
Alan N. Houghton - New York NY
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
A61K 4505, A01H 6300, C07K 1600
US Classification:
4241311
Abstract:
A vaccine for stimulating and enhancing in a subject to which the vaccine is administered, production of antibodies which recognize GD3 ganglioside, comprising an effective amount of anti-idiotypic monoclonal antibody, designated BEC2, an effective amount of the appropriate adjuvant and a pharmaceutically acceptable vehicle.
Anti-Idiotypic Monoclonal Antibody That Induces An Immune Response Against The Ganglioside Gd.sub.3 And Hybridoma Producing Said Antibody
US Patent:
5529922, Jun 25, 1996
Filed:
May 22, 1995
Appl. No.:
8/445906
Inventors:
Paul B. Chapman - New York NY
Alan N. Houghton - New York NY
Alan N. Houghton - New York NY
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
C12N 520, C07K 1642
US Classification:
43524027
Abstract:
The invention provides an anti-idiotypic monoclonal antibody, IgG2b subclass, which specifically induces an immune response against the GD. sub. 3 ganglioside and specifically binds to the binding site of the R24 antibody.
Methods For Detecting Circulating Mutant Braf Dna
US Patent:
7442507, Oct 28, 2008
Filed:
Jan 24, 2006
Appl. No.:
11/338615
Inventors:
David Polsky - Ardsley NY, US
Iman Osman - Port Liberte NJ, US
Paul B. Chapman - New York NY, US
Iman Osman - Port Liberte NJ, US
Paul B. Chapman - New York NY, US
Assignee:
New York University School of Medicine - New York NY
Memorial Sloan-Kettering Cancer Center - New York NY
Memorial Sloan-Kettering Cancer Center - New York NY
International Classification:
C12Q 1/68
US Classification:
435 6, 435 911, 435 912
Abstract:
The present invention relates to a method for detecting the presence of circulating mutant BRAF DNA, which may be present in circulating melanoma cells or as DNA shed from tumor cells. Methods, compositions and kits which employ one or more sets of BRAF mutant specific primer pairs for detection of circulating mutant BRAF DNA are presented. Also provided are methods for diagnosing and/or determining stage/progression of a melanoma in a mammal based on detection of a BRAF mutant nucleic acid sequence. Such methods are also well suited to monitoring disease activity in patients with active disease or those in remission.
Anti Ganglioside Gd3 Antibodies And Uses Thereof
US Patent:
8207308, Jun 26, 2012
Filed:
Aug 16, 2009
Appl. No.:
12/541958
Inventors:
Paul Chapman - New York NY, US
Lisa Davidson - Edingburgh, GB
José W. Saldanha - Middlesex, GB
Lisa Davidson - Edingburgh, GB
José W. Saldanha - Middlesex, GB
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
C12P 21/08
US Classification:
5303873, 5303877, 5303888, 5303913
Abstract:
The present invention is related to complementarity determining region (cdr)-grafted humanized r24 antibodies that bind to the gd3 ganglioside antigen. The humanized antibodies disclosed herein have characteristics that are comparable or superior to the murine r24 antibody, and the humanized antibodies are useful in treating cancer (e. g. Melanoma).
Anti-Idiotypic Antibody Which Induces An Immune Response Against A Glycosphingolipid And Use Thereof
US Patent:
2003003, Feb 20, 2003
Filed:
Aug 13, 2002
Appl. No.:
10/218725
Inventors:
Paul Chapman - New York NY, US
Alan Houghton - New York NY, US
Alan Houghton - New York NY, US
Assignee:
Sloan-Kettering Institute for Cancer Research
International Classification:
A61K039/395, C12N005/06, C07K016/44
US Classification:
424/131100, 530/387200, 435/327000
Abstract:
The present invention provides an anti-idiotypic monoclonal antibody which specifically induces an immune response against a glycosphingolipid. Additionally, this invention provides a method of producing the anti-idiotypic monoclonal antibody. Finally, this invention provides a composition of matter comprising an effective amount of a cytokine and a melanoma ganglioside-specific antibody attached to a carrier.